Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
103 hedge funds and large institutions have $499M invested in Akero Therapeutics in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
6% more funds holding
Funds holding: 97 → 103 (+6)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.71% less ownership
Funds ownership: 101.23% → 100.52% (-0.71%)
33% less capital invested
Capital invested by funds: $746M → $499M (-$247M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $460K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.23M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.62M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$3.59M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$2.01M |
| 5 |
Morgan Stanley
New York
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.3M |
| 2 |
Goldman Sachs
New York
|
-$11.8M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.88M |
| 4 |
Alkeon Capital Management
New York
|
-$1.05M |
| 5 |
BlackRock
New York
|
-$851K |
AKRO Hedge Fund Activity: Q1 2022 in Review
103 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2022, worth a combined $499M — down 33% from $746M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AKRO positions and 8 closed out — a net gain of 6 holders — while 35 added to existing stakes and 25 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $6.23M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.3M.
- 103 institutional investors held Akero Therapeutics (AKRO) as of Q1 2022, up from 97 in Q4 2021.
- Funds reported $499M of Akero Therapeutics stock for Q1 2022, down 33% quarter-over-quarter.
- 14 funds opened new Akero Therapeutics positions in Q1 2022 and 8 closed out, a net change of +6 holders.
- The largest Akero Therapeutics buyer in Q1 2022 was Wellington Management Group, an estimated $6.23M added.
- The largest Akero Therapeutics seller in Q1 2022 was T. Rowe Price Associates, an estimated $12.3M sold.
Based on aggregated 13F filings for Q1 2022.